Lanreotide for Advanced Pancreatic Cancer
Author Information
Author(s): Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, Kornek G V, Vorbeck F, Hejna M H L, Virgolini I, Scheithauer W
Primary Institution: University of Vienna
Hypothesis
Can the long-acting somatostatin analogue lanreotide effectively treat advanced pancreatic cancer?
Conclusion
The study found that lanreotide did not lead to any objective responses in patients with advanced pancreatic cancer, and the median survival was only 4 months.
Supporting Evidence
- No objective response was obtained from the treatment.
- The median survival of patients was 4 months.
- SST-receptor scintigraphy could not visualize pancreatic cancer in patients.
- In vitro data showed absence of SSTR2 expression in pancreatic cancer.
Takeaway
Doctors tried a medicine called lanreotide on 14 people with a serious type of cancer, but it didn't help them live longer.
Methodology
Fourteen patients with metastatic pancreatic adenocarcinoma were treated with lanreotide, and in vitro studies were conducted to assess SSTR2 expression.
Limitations
The study had a small sample size and no objective responses were observed.
Participant Demographics
Patients had metastatic pancreatic adenocarcinoma.
Statistical Information
Confidence Interval
1.8–7 months
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website